-
Special Review
-
Korean J Med. 2014;87(1):9-13. Published online July 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.87.1.9
- 글루카곤양 펩티드-1 유사체
-
엄영실, 김병준
-
가천대학교 길병원 내과
- Glucagon-Like Peptide-1 (GLP-1) Agonist
-
Young Sil Eom, Byung-Joon Kim
-
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
- Corresponding author: Byung-Joon Kim ,Tel: +82-32-460-8903, Fax: +82-32-469-4320, Email: kbjoon4u@gilhospital.com
-
- Abstract
- The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications.
Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are
suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient
intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists
and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus.
The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes.
Keywords :Glucagon-like peptide 1 analogue, Incretin, Type 2 diabetes
